Do More With Reuters
Partner Services

India Ranbaxy gets FDA nod for cyclobenzaprine HCL

Thu May 15, 2008 9:02am IST
 
Email | Print | | Single Page
[-] Text [+]

MUMBAI, May 15 (Reuters) - Indian drugmaker Ranbaxy Laboratories Ltd (RANB.BO: Quote, Profile, Research) has received approval from the U.S. Food and Drug Administration for muscle relaxant cyclobenzaprine hydrochloride tablets, the regulator's website showed.

The FDA has also granted tentative approval to Lupin Pharmaceuticals Inc, a unit of Lupin Ltd (LUPN.BO: Quote, Profile, Research), for ramipril capsules, used in treating cardiovascular disease and high blood pressure. (Reporting by Rina Chandran; Editing by John Mair)

Construction workers work at a site as the sun sets in Chandigarh in this December 2006 file photo. REUTERS/Ajay Verma
Economy seen growing at 7.2 pct in FY10 - govt

The forecast reinforces the possibility that the government may start to unwind its fiscal stimulus in the budget.  Full Article 

Market Update

  • IndiaIndia
  • USUS
  • UKUK
  • Asia
  • Most Actives
Greece's Finance Minister Papaconstantinou addresses reporters during a news conference in Athens, January 20, 2010.
Eurozone agreed in principle to aid Greece

Euro zone countries have decided in principle to help debt-stricken Greece, a senior German ruling coalition source said.  Full Article 

FROM THE MARKETS

After the Bell
After the Bell

Reuters Money's Kshitij Anand updates you on the movers and shakers of the Indian stock market.  Blog 

SHOWCASE

"Claw Back" Pay
"Claw Back" Pay

Banks and regulators hope that threats to "claw back" pay if trades later blow up will rein in risk taking on Wall Street.  Full Article 

 
James Saft
Blaming Asperger's

COLUMN - Did Asperger's help cause the financial crisis?  Full Article 

 
Going Global
Going Global

With Volvo, Chinese eye M&A abroad to win at home.  Full Article 

 
Delivery Woes
Delivery Woes

Boeing 787 delivery schedule could slip - experts.  Full Article 

 
Central Banks Cautious
Central Banks Cautious

Reuters tracks the policies of the world's top central banks as the debate over global economic recovery rages on.   Full Coverage